The American scientists from Purdue University and Indiana University
defined a biomarker which will allow to predict multiple sclerosis at an early stage.
Physicians found out what can be used for diagnosis of multiple sclerosis. This molecule is considered a by-product of metabolism which collects at people with such neurologic diseases as multiple sclerosis and Parkinson's disease, and sometimes as a result of injuries of a spinal cord and brain
It is considered that damages cages, destroying lipids (so-called oxidation of lipids).Scientists could measure the level of an akrolein at people and animals and came to a conclusion that the high level of an akrolein is an indicator of development of multiple sclerosis.It is not yet clear whether scientists should target the fight against acrolein, the therapeutic effect of removing acrolein from the body has yet to be established.
About 2.3 million people worldwide suffer from multiple sclerosis.The disease is usually diagnosed aged from 20 up to 50 years and affects twice more women, than men.Exact causes of illness therefore multiple sclerosis medicine does not exist are not known yet.Doctors can only stop the mechanisms of the disease.If hopes of scientists on are equaled, physicians will have an opportunity to control efficiency of treatment of multiple sclerosis.